A Phase 1 interventional study of ZB002 and Placebo in Healthy Volunteers and Rheumatoid Arthritis, sponsored by Zenas BioPharma (USA), LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Zenas BioPharma (USA), LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 118th largest by enrollment of the 140 interventional ones that give a count, is one of 2 that started in 2022, is one of 21 in phase 1, and was the 135th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in Australia
Ages 18–75 · Healthy volunteers
The Bionics Institute of Australia · Sites in Australia
Ages 18–75
Candid Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
Kali Therapeutics, Inc. · Sites in Australia, New Zealand
Ages 18–75
Seismic Therapeutic AU Pty Ltd · Sites in Australia
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 72 · Phase 4 13
First in 2000; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 469 across the 140 interventional studies, 559 across the 13 observational. Of the 131 that completed or were terminated, 94 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 154 have an industry lead sponsor. The 10 most frequent:
Zenas BioPharma (USA), LLC is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Zenas BioPharma (USA), LLC has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07234773Kali Therapeutics, Inc.A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). | 2027-02 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07017686The Bionics Institute of AustraliaThe Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis | 2027-09 |
| NCT07455578Seismic Therapeutic AU Pty LtdStudy of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts. Part A: Single Ascending Dose (SAD), which will include only healthy volunteers. Part B: Multiple Ascending Dose (MAD), will commence after completion of the SAD study and will include RA participants.
Part A (SAD): Up to approximately 48 healthy volunteers across 6 cohorts randomized to receive ZB002 or placebo as a single dose.
Part B (MAD): Up to approximately 24 participants with RA across 3 cohorts randomized to receive ZB002 or placebo as multiple doses.
Main Inclusion Criteria
Part A SAD (HV):
Part B MAD (RA Participants):
Main Exclusion Criteria
Part A SAD (HV):
Part B MAD (RA Participants):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers will receive a single dose of ZB002 or placebo
Drug: ZB002 · Drug: Placebo
RA participants will receive ZB002 or placebo every 4 weeks (Q4W) × 3 administrations
Drug: ZB002 · Drug: Placebo
ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
Placebo will be administered subcutaneously as per schedule specified in the respective arm.
ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Part A: Safety and Tolerability in HVs
To evaluate the safety and tolerability of ZB002 in HVs by assessing the number, severity and type of adverse events, including changes in laboratory safety test and electrocardiogram (ECG)
Time frame: Day 1 through Day 120
Part B: Safety and Tolerability of multiple doses of ZB002 in participants with RA
To evaluate the safety and tolerability of ZB002 in participants with RA by assessing the number of participants with Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAE leading to discontinuation
Time frame: Day 1 through Day 176
Part A: Maximum observed serum concentration (Cmax)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: Time for Cmax (Tmax)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: AUC from time 0 to the last quantifiable concentration (AUClast)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: Terminal half-life (t1/2)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: Apparent clearance following extravascular dosing (CL/F)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part A: Apparent volume of distribution following extravascular administration (Vz/F)
Pharmacokinetics
Time frame: Day 1 through Day 120
Part B (All Doses): Serum trough concentration (Ctrough)
Before repeat-dose administration (or at the end of the dosing interval \[tau\] after the final dose)
Time frame: Day 1 through Day 176
Part B (Doses 1 and 3): Maximum observed serum concentration (Cmax)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Doses 1 and 3): Time for Cmax (Tmax)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Doses 1 and 3): AUC over the dosing interval, tau (AUCtau)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Doses 1 and 3): Accumulation ratio of Cmax (ARCmax)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Doses 1 and 3): Accumulation ratio of AUC (ARAUC)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Dose 3 only): Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Dose 3 only): Terminal half-life (t1/2)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Dose 3 only): AUC from time 0 to the last quantifiable concentration (AUClast)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Dose 3 only): Apparent clearance following extravascular dosing (CL/F)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B (Dose 3 only): Apparent volume of distribution following extravascular (Vz/F)
Pharmacokinetics
Time frame: Day 1 through Day 176
Part B: Serum anti-ZB002 antibody prevalence and incidence
Time frame: Day 1 through Day 176
Part B: Cytokine/chemokine secretion in ex vivo stimulated whole blood
Pharmacodynamic
Time frame: Day 1 through Day 176
Ran from Dec 2022 to primary completion in Feb 2026, 38 months.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 38 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zenas BioPharma (USA), LLC